In today’s briefing:
- RecBio (江苏瑞科) Pre-IPO: Thoughts on Valuation
RecBio (江苏瑞科) Pre-IPO: Thoughts on Valuation
- RecBio is an innovative vaccine company with a focus on HPV vaccines. The company is pre-marketing its USD 100-200 million Hong Kong listing.
- In the previous note, we looked at the company’s core products, including its HPV portfolio and the COVID-19 vaccine. Though not impressive, it does provide exposure to China HPV market.
- In this insight, we provide our thoughts on valuation, including key assumptions.
Before it’s here, it’s on Smartkarma
